

Referencias

1. Saluja S, Anderson SG, Hambleton I, Shoo H, Livingston M, Jude EB, et al. Foot ulceration and its association with mortality in diabetes mellitus: a meta-analysis. *Diabet Med J Br Diabet Assoc.* febrero de 2020;37(2):211–8.
2. Brownrigg JRW, Davey J, Holt PJ, Davis WA, Thompson MM, Ray KK, et al. The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes: a meta-analysis. *Diabetologia* [Internet]. 1 de noviembre de 2012 [citado 12 de marzo de 2020];55(11):2906–12. Disponible en: <https://doi.org/10.1007/s00125-012-2673-3>
3. van Netten JJ, Price PE, Lavery LA, Monteiro-Soares M, Rasmussen A, Jubiz Y, et al. Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review. *Diabetes Metab Res Rev.* enero de 2016;32 Suppl 1:84–98.
4. Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis †. *Ann Med.* 2017;49(2):106–16.
5. Shojaiefard A, Khorgami Z, Larijani B. Independent risk factors for amputation in diabetic foot. *Int J Diabetes Dev Ctries* [Internet]. 2008 [citado 12 de marzo de 2020];28(2):32–7. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2772008/>
6. Houtum WH van. Barriers to the delivery of diabetic foot care. *The Lancet* [Internet]. 12 de noviembre de 2005 [citado 2 de agosto de 2017];366(9498):1678–9. Disponible en: [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(05\)67675-1/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67675-1/abstract)
7. Orientación Técnica del Manejo Integral del Pie Diabético. [Internet]. [citado 20 de marzo de 2020]. Disponible en: https://redcronicas.minsal.cl/wp-content/uploads/2020/01/2019.12.10_OT-PIE-DIABETICO.pdf
8. Standards of Medical Care in Diabetes-2017: Summary of Revisions. *Diabetes Care.* enero de 2017;40(Suppl 1):S4–5.
9. Guías_ALAD_2009.pdf [Internet]. [citado 8 de septiembre de 2017]. Disponible en: http://www1.paho.org/hq/dmdocuments/2010/Guías_ALAD_2009.pdf
10. Williams LH, Rutter CM, Katon WJ, Reiber GE, Ciechanowski P, Heckbert SR, et al. Depression and incident diabetic foot ulcers: a prospective cohort study. *Am J Med.* agosto de 2010;123(8):748-754.e3.
11. Maydick DR, Acee AM. Comorbid Depression and Diabetic Foot Ulcers. *Home Healthc Now.* febrero de 2016;34(2):62–7.

12. Hingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. *J Vasc Surg.* febrero de 2016;63(2 Suppl):3S-21S.
13. Best practice guidelines: Wound management in diabetic foot ulcers - Wounds International [Internet]. [citado 7 de septiembre de 2017]. Disponible en: <http://www.woundsinternational.com/best-practices/view/best-practice-guidelines-wound-management-in-diabetic-foot-ulcers>
14. Ministerio de Salud de Chile. Orientación Técnica:Prevención de Úlcera de los pies en la persona con Diabetes . 2013.
15. International Diabetes Federation: Clinical Practice Recommendations on the Diabetic Foot: A guide for health care professionals: International Diabetes Federation, 2017 [Internet]. [citado 30 de octubre de 2017]. Disponible en: <https://www.idf.org/e-library/guidelines/119-idf-clinical-practice-recommendations-on-diabetic-foot-2017.html>
16. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care.* abril de 2005;28(4):956–62.
17. Diabetic foot problems: prevention and management | Guidance and guidelines | NICE [Internet]. [citado 1 de agosto de 2017]. Disponible en: <https://www.nice.org.uk/guidance/ng19>
18. Booth J, Young MJ. Differences in the performance of commercially available 10-g monofilaments. *Diabetes Care.* julio de 2000;23(7):984–8.
19. Boulton AJM, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, et al. Comprehensive Foot Examination and Risk Assessment. *Diabetes Care.* agosto de 2008;31(8):1679–85.
20. Júbiz GMY, Alvaro Márquez JB, et al. Guías colombianas para la prevención, diagnóstico y tratamiento del pie diabético. Grupo Colombiano de Pie Diabético; 2012.
21. Waldfogel JM, Nesbit SA, Dy SM, Sharma R, Zhang A, Wilson LM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. *Neurology.* 16 de mayo de 2017;88(20):1958–67.
22. Tools for Assessing Neuropathic Pain [Internet]. [citado 2 de abril de 2018]. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661248/>
23. Mathieson S, Maher CG, Terwee CB, Folly de Campos T, Lin C-WC. Neuropathic pain screening questionnaires have limited measurement properties. A systematic review. *J Clin Epidemiol.* agosto de 2015;68(8):957–66.

24. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). *Pain*. marzo de 2005;114(1-2):29-36.
25. Spallone V, Morganti R, D'Amato C, Greco C, Cacciotti L, Marfia GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. *Diabet Med J Br Diabet Assoc*. mayo de 2012;29(5):578-85.
26. Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, et al. Using screening tools to identify neuropathic pain. *Pain*. febrero de 2007;127(3):199-203.
27. Perez C, Galvez R, Huelbes S, Insausti J, Bouhassira D, Diaz S, et al. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. *Health Qual Life Outcomes* [Internet]. 4 de diciembre de 2007 [citado 2 de abril de 2018];5:66. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2217518/>
28. Brownrigg JRW, Apelqvist J, Bakker K, Schaper NC, Hinchliffe RJ. Evidence-based Management of PAD & the Diabetic Foot. *Eur J Vasc Endovasc Surg*. 1 de junio de 2013;45(6):673-81.
29. Peripheral arterial disease: diagnosis and management | Guidance and guidelines | NICE [Internet]. [citado 2 de abril de 2018]. Disponible en: <https://www.nice.org.uk/guidance/cg147>
30. Marso SP, Hiatt WR. Peripheral Arterial Disease in Patients With Diabetes. *J Am Coll Cardiol*. 7 de marzo de 2006;47(5):921-9.
31. Au TB, Golledge J, Walker PJ, Haigh K, Nelson M. Peripheral arterial disease - diagnosis and management in general practice. *Aust Fam Physician*. junio de 2013;42(6):397-400.
32. Pérez JAM, Vitarella G, Guzmán JR, Pedrosa HC, Braver JD, Soto NR, et al. Guías ALAD de Pie Diabético—GLEPED. *Asoc Latinoam Diabetes* [Internet]. 2010 [citado 8 de septiembre de 2017];XVIII. Disponible en: <http://soched.cl/Guias-alad-pie-diabetico.doc>
33. Halperin JL. Evaluation of patients with peripheral vascular disease. *Thromb Res* [Internet]. 1 de junio de 2002 [citado 2 de abril de 2018];106(6):V303-11. Disponible en: <http://www.sciencedirect.com/science/article/pii/S0049384801003668>
34. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. *J Am Coll Cardiol*. 7 de marzo de 2006;47(5):921-9.
35. Kästenbauer T, Sauseng S, Sokol G, Auinger M, Irsigler K. A Prospective Study of

Predictors for Foot Ulceration in Type 2 Diabetes. J Am Podiatr Med Assoc [Internet]. 1 de julio de 2001 [citado 5 de abril de 2018];91(7):343–50. Disponible en: <http://www.japmaonline.org/doi/abs/10.7547/87507315-91-7-343>

36. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med J Br Diabet Assoc. mayo de 2002;19(5):377–84.

37. Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG. A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care. julio de 1999;22(7):1036–42.

38. Pie y tobillo diabéticos [Internet]. [citado 5 de abril de 2018]. Disponible en: <http://www.docenciatraumatologia.uc.cl/2016-04-27-20-46-23/pie-tobillo-diabeticos-patologia-no-traumatica-t>

39. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 15 de mayo de 2008;473(2):139–46.

40. La neuroartropatía de Charcot en el pie diabético [Internet]. [citado 11 de abril de 2018]. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S2306-41022016000100033

41. ORIENTACIONES 2017 AYUDAS TÉCNICAS: DEFINICIÓN, CLASIFICACIÓN Y ESPECIFICACIONES [Internet]. [citado 23 de marzo de 2020]. Disponible en: https://diprece.minsal.cl/wrdprss_minsal/wp-content/uploads/2017/12/OT-AYUDAS-T%C3%89CNICAS-DEFINICI%C3%93N.pdf

42. Burns J, Wegener C, Begg L, Vicaretti M, Fletcher J. Randomized trial of custom orthoses and footwear on foot pain and plantar pressure in diabetic peripheral arterial disease. Diabet Med J Br Diabet Assoc. septiembre de 2009;26(9):893–9.

43. Rizzo L, Tedeschi A, Fallani E, Coppelli A, Vallini V, Iacopi E, et al. Custom-made orthosis and shoes in a structured follow-up program reduces the incidence of neuropathic ulcers in high-risk diabetic foot patients. Int J Low Extrem Wounds. marzo de 2012;11(1):59–64.